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ABSTRACT
We performed a retrospective cohort study of patients
with chronic obstructive lung disease (COPD) on longterm oxygen treatment (LTOT) who received invasive
mechanical ventilation for COPD exacerbation. Of the
4791 patients, 23% died in the hospital, and 45% died
in the subsequent 12 months. 67% of patients were
readmitted at least once in the subsequent 12 months,
and 26.8% were discharged to a nursing home or
skilled nursing facility within 30 days. We conclude that
these patients have high mortality rates, both in-hospital
and in the 12 months postdischarge. If patients survive,
many will be readmitted to the hospital and discharged
to nursing home. These potential outcomes may support
informed critical care decision making and more
preference congruent care.

mortality, readmissions and discharge to nursing
home. Further, we describe the association between
patient-level factors such as comorbidities and
nursing home residence, and these outcomes.

METHODS
We conducted a cohort study of Medicare
Beneﬁciaries who were hospitalised for a COPD
exacerbation in 2008. The analytic dataset included
2007–2009 data from the following CMS data
ﬁles: the Master Beneﬁciary Summary File Base
Segments; the Medicare Provider Analysis and
Review utilisation ﬁles (MEDPAR); the Home
Health, Hospice and Durable Medical Equipment
(DME) utilisation ﬁles; and Minimum Data Set
(MDS).

Cohort selection
INTRODUCTION
Chronic obstructive lung disease (COPD) is the
third leading cause of death in the USA. The
disease follows a progressive course, and patients
with advanced disease most often die from respiratory failure or cardiovascular disease. Patients hospitalised for respiratory failure due to COPD
(COPD exacerbation) have a 2-year median survival, and 50% of patients who survive hospitalisation are readmitted within 6 months of discharge.1
In addition, patients with COPD are more likely to
die after receiving life-supporting technologies and
less likely to receive palliative care compared with
lung cancer patients.2 Unless patients explicitly
choose to forego invasive treatments, often the
default is to ‘do everything’ to prolong survival.
However, survivors of invasive treatments often
have decreased functional capacity, are discharged
to a nursing home and have recurrent hospitalisations that may adversely impact quality of life.
Knowledge of these potential outcomes may
inﬂuence patients’ informed decision making about
whether to accept invasive mechanical ventilation.
Unfortunately, few studies have measured outcomes
beyond hospital survival for patients with COPD.
In this study, we describe outcomes for patients
with COPD on LTOT who are admitted to an ICU
for respiratory failure and receive invasive mechanical ventilation. The focus of our analysis is on outcomes that may inform patient-level decision
making about whether to accept invasive mechanical ventilation, including in-hospital and 12-month

We conﬁned the cohort to beneﬁciaries with diagnoses of COPD, with at least two claims for LTOT,
admitted to non-rural ICUs, for COPD exacerbation,
treated with invasive mechanical ventilation (4791
patients) (see online supplementary ﬁgure S1).

Patient characteristics
We collected data on the patient’s age, race and
sex, as well as nursing home or skilled nursing facility (SNF), admission before the index admission.
We derived Elixhauser comorbidity measures based
on the ICD-9 codes.

Patient outcomes
Primary outcomes were (1) in-hospital and
12-month mortality, (2) all-cause readmission over
12 months and (3) discharge to nursing home or
SNF within 30 days. We measured discharge to
nursing home using data from MDS entry dates.

Statistical analysis
We described patient characteristics using counts
and proportions for all variables, except for age,
for which we reported a mean (SD) value. We used
bootstrap methods to estimate 95% CIs for the
proportions.
We tested the association of individual patient-level
factors on mortality (in-hospital and 12-month) and
readmission (12-month) using simple logistic regression. Fully adjusted models were estimated using multiple logistic regression and a backwards elimination
variable selection algorithm. ORs and 95% CIs were
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RESULTS
The study cohort was deﬁned as the 4791 COPD-LTOT patients
who received invasive mechanical ventilation for COPD exacerbation. Mean age was 74.3 (SD 6.4), and 88.2% were white.
14.3% (n=687) were in a nursing home or SNF within
365 days before the index admission (deﬁned as the ﬁrst ICU
admission in 2008) (see online supplementary table S1). Most
patients (69.8%) had more than three comorbidities.

Mortality
Of the 4791 COPD-LTOT patients who received invasive mechanical ventilation for COPD exacerbation, 23.3% died in the
hospital and 45.2% died in the 12 months after hospital discharge (ﬁgure 1). Of the total cohort, 31.5% were alive 1 year
following discharge.

(AOR 1.30), renal failure (AOR 1.42) and metastatic cancer
(AOR 1.92). Obesity was associated with reduced mortality
(AOR 0.71).
Among patients discharged alive (n=3677), the odds of dying
within 12 months increased by 1% for every 1 year increase in
age (AOR 1.01; 95% CI 1.01 to 1.01). Other factors associated
with dying within 12 months included white race (50.6% vs
46.5%; AOR 1.07); male sex (52.4% vs 48.5%; AOR 1.04) and
nursing home admission at any point in previous year (63.6%
vs 48.0%; AOR 1.10). The following comorbidities were associated with a higher likelihood of dying within 12 months: ﬂuid
and electrolyte disorders (AOR 1.05), weight loss (AOR 1.12),
solid tumour without metastasis (AOR 1.20) and metastatic
cancer (AOR 1.23). Obesity was associated with reduced mortality (AOR 0.91).

Factors associated with readmission

Of the 3677 index admission survivors, 67.1% were readmitted
at least once in the subsequent 12 months, and 45.3% were
rehospitalised two or more times (ﬁgure 1). Of those with at
least one readmission (n=2466), 52.1% were readmitted due to
COPD.

(See online supplementary table S3). The odds of readmission
were increased by 14% if patients were admitted to a nursing
home within 30 days of discharge from the hospital (75.6% vs
64.5%, AOR 1.14; 95% CI 1.10 to 1.18). The following
comorbidities were associated with a higher likelihood of
readmission within 12 months: congestive heart failure (AOR
1.06), diabetes (AOR 1.06), deﬁciency anemias (AOR 1.05) and
depression (AOR 1.05).

Discharge to nursing home

DISCUSSION

Of the 3177 patients discharged alive who were not in a nursing
home in the 12 months before the index admission, 26.8%
were admitted to a nursing home within 30 days after hospital
discharge. An additional 12.3% of survivors were admitted to a
nursing home after 30 days.

We describe outcomes over 12 months for patients with COPD
on LTOT who are treated with invasive mechanical ventilation
for acute COPD exacerbation. Beyond mortality, we provide
insights into the clinical care trajectories for patients after mechanical ventilation in terms of readmission and nursing home
admission.
Patients with advanced COPD are at increased risk for severe
COPD exacerbations that require critical care. Our work may be
useful to inform patients’ decision making about whether to
accept invasive mechanical ventilation in the event of respiratory
failure due to COPD exacerbation, by describing and quantifying survival and outcomes that may affect quality of life such as
rehospitalisation and admission to nursing home.
In prior work, we designed a Markov decision model to simulate outcomes for patients with severe COPD who chose

Readmissions

Factors associated with mortality
(See online supplementary table S2). The odds of dying in the
hospital increased by 4% for every 1 year increase in age
(adjusted OR (AOR), 1.04; supplement, 95% CIs). Other
factors associated with hospital death included: white race
(23.8% vs 18.9%; AOR 1.42); male sex (25.3% vs 21.7%;
AOR 1.17); and nursing home admission at any point in previous year (27.2% vs 22.6%; AOR 1.27). The following
comorbidities were associated with hospital death: weight loss

Figure 1 Outcomes over 12 months for patients with COPD-LTOT treated with invasive mechanical ventilation (with 95% CIs). COPD-LTOT, chronic
obstructive lung disease–long-term oxygen treatment.
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estimated for each of the analyses. For additional description of
methods, see online supplementary material.
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alternative advance directives for mechanical ventilation. We
estimated 54% 12-month mortality for severe patients with
COPD who chose to receive invasive mechanical ventilation
(Full Code advance directives) versus 57% for patients who
chose not to receive invasive mechanical ventilation.3 However,
Full Code patients had increased rehospitalisations and discharge to nursing home. Other investigators have indicated high
mortality for patients with COPD who require mechanical ventilation for COPD-related respiratory failure. Breen et al
describe 48.6% 12-month mortality in a retrospective cohort of
74 patients admitted to the ICU with acute respiratory failure
due to COPD.4
COPD is a leading cause of hospital readmissions. Most
studies report 30-day readmission because this may be more
likely a marker of quality of care. The goal of our analysis was
to describe outcomes that may be helpful for patients in decision making, and we therefore describe longer-term readmission
rates. These readmissions likely reﬂect the severity of underlying
chronic disease and the ‘end-of-life’ stage of COPD, although
the proportion of potentially preventable admissions cannot be
measured by this analysis.
In contrast to mortality and readmission rates, few studies
have described discharge to nursing home after mechanical ventilation for COPD respiratory failure. Although our current analysis does not include data to assess functional capacity, more
than 60% of nursing home residents who have COPD require
extensive assistance, or are totally dependent for activities of
daily living in other studies.5 In addition, many patients are
unable to be liberated from mechanical ventilation1 and many
of the 26.8% of patients we identiﬁed as being discharged to
nursing home within 30 days may have remained on mechanical
ventilation. Understanding the likelihood of nursing home
admission after mechanical ventilation for COPD exacerbation,
described in our study, may be valuable for patients’ decision
making.
Our study has several limitations. Most notably, we used
LTOT as a marker of COPD severity. We chose this method as a
surrogate marker of advanced/severe COPD because CMS data
ﬁles do not contain lung function tests. We believe oxygen supplementation is a valid surrogate marker of COPD severity
because patients with COPD typically require oxygen supplementation once their lung disease is very advanced. Second,
there are limits on the generalisability of our outcomes because
the cohort was predominantly white and did not include
patients admitted to rural hospitals where practice patterns are
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likely different. Third, because this was a course-of-disease
study, we did not compare outcomes from another group, such
as an exacerbated COPD cohort who did not receive invasive
mechanical ventilation. A meaningful comparison would require
the groups to have similar characteristics (eg, health status and
acuity of illness) at the time of ICU admission, which we could
not ascertain with the available data.
The outcomes we report have important implications for
doctor–patient discussions about prognoses in the event of acute
COPD exacerbation and could be useful to patients making
informed decisions about whether to accept invasive mechanical
ventilation. Future work will describe the quality of life for
patients discharged to a nursing home in an attempt to further
inform advance care planning in patients with advanced COPD.
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